Inactive Instrument

Sienna Cancer Diagnostics Limited Stock

SDX

AU000000SDX1

Chart Sienna Cancer Diagnostics Limited

Duration

Period

Style

Dynamic Chart

Latest news about Sienna Cancer Diagnostics Limited

BARD1 Life Sciences Limited completed the acquisition of Sienna Cancer Diagnostics Limited from Merchant Funds Management Pty Ltd and other shareholders.	20-07-27	CI
Sienna Cancer Diagnostics Announces Change of Registered Office	20-06-26	CI
Sienna Cancer Diagnostics Limited Announces Distribution Agreement with Aenorasis S.A	20-06-18	CI
Sienna Cancer Diagnostics Appoints Triolab AB Exclusive Distributor in Sweden	20-06-01	CI
Sienna Cancer Diagnostics Limited Announces Distribution Agreement with Zotal Ltd	20-05-20	CI
Sienna Cancer Diagnostics Ltd. Appoints Scientle Innovations as its Exclusive Distributor in New Zealand	20-05-05	CI
Sienna Cancer Diagnostics Ltd H Enters into an Exclusive Worldwide Licence Agreement with the University of Adelaide to Develop and Commercialise Unique Cancer Probe, SubB2M	20-04-19	CI
BARD1 Life Sciences Limited entered into a merger implementation agreement to acquire Sienna Cancer Diagnostics Limited for AUD 24.7 million.	20-04-07	CI
Sienna Cancer Diagnostics Limited Appoints Geoff Mccaughan to Its Recently Formed Clinical Advisory Board	20-03-15	CI
Sienna Cancer Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-20	CI
Sienna Cancer Diagnostics Limited Appoints Immuno Diagnostic Oy as an Exclusive Distributor in Finland	20-02-05	CI
Sienna Cancer Diagnostics Limited Appoints Tony Di Pietro as a Director of its Board	20-02-05	CI
Sienna Cancer Diagnostics Limited Announces Clinical Advisory Board Appointments	20-01-29	CI
Sienna Cancer Diagnostics Ltd Announces the Initiation of South Korean Clinical Study Utilising the Company's Novel Adjunct Urine Cytology Test, the hTERT test	20-01-21	CI
Sienna Cancer Diagnostics Ltd Announces That Non-Executive Director, David J. Earp, Jd, Has Stepped Down Effective 14 November 2019	19-11-13	CI

More news

Press releases Sienna Cancer Diagnostics Limited

Sienna Cancer Diagnostics : Closes Rights Issue Offer	20-02-24	PU
Sienna Cancer Diagnostics : makes Board Appointment	20-02-05	PU
Sienna Cancer Diagnostics : Increases European Presence Expanding into Finland with hTERT test	20-02-05	PU
Sienna Cancer Diagnostics : Appendix 4C and Report on Quarterly Activities	20-01-31	PU
Sienna Cancer Diagnostics : Substantial Take-up of Rights Issue Shortfall	20-01-21	PU

More press releases

Managers and Directors - Sienna Cancer Diagnostics Limited

Members of the board	Title	Age	Since
Philip Powell BRD	Director/Board Member	65	20-07-27

More insiders

Sienna Cancer Diagnostics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel in vitro diagnostic (IVD) tests for detection and monitoring of cancer. The Company manufactures IVD products for pathology laboratories to use in testing services. The Company's product Anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) is based on a technology for the detection of biomarker telomerase.The hTERT can be used in pathology labs. Anti-hTERT is targeted against hTERT protein component of the telomerase complex which acts to extend and maintain telomeres in cells.

Sector

More about the company